Glyset Related Published Studies
Well-designed clinical trials related to Glyset (Miglitol)
Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. [2011.03]
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. [2011.03]
Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. [2010]
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. [2010]
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. [2008.09]
Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus. [2007.06]
Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. [2007]
Well-designed clinical trials possibly related to Glyset (Miglitol)
Comparing the efficacy of alpha-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. [2011.03]
Other research related to Glyset (Miglitol)
Comparisons of the effects of 12-week administration of miglitol and voglibose on
the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic
patients. [2012]
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. [2011.11.03]
Effect of 3-Month Repeated Administration of Miglitol on Vascular Endothelial Function in Patients With Diabetes Mellitus and Coronary Artery Disease. [2011.09.23]
Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines. [2011.05]
Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol. [2011.02]
Evaluation of the efficacy and tolerability of miglitol in Chinese patients with
type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. [2011]
Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. [2010.07.09]
Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -. [2010.07]
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor miglitol. [2010]
Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels. [2009.10.01]
The alpha-glucosidase inhibitor miglitol suppresses postprandial hyperglycaemia and interleukin-1beta and tumour necrosis factor-alpha gene expression in rat peripheral leucocytes induced by intermittent sucrose loading. [2009.07]
The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. [2009.06]
Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. [2009.03]
Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. [2009.01]
Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. [2007.11]
Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. [2007.10]
Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats. [2007.10]
Other possibly related research studies
Alpha-glucosidase inhibitors for type 2 diabetes mellitus. [2005.04.18]
Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. [2005]
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. [2005.01]
[Iminosugars: current and future therapeutic applications] [2007.01]
Glucose supply and insulin demand dynamics of antidiabetic agents. [2010.03.01]
Synthesis of iminoalditol analogues of galactofuranosides and their activities against glycosidases. [2008.11.24]
Reduced expression of beta2 integrin genes in rat peripheral leukocytes by inhibiting postprandial hyperglycemia. [2010]
Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. [2010.06]
Advances in the treatment of type 2 diabetes mellitus. [2011.03]
|
